Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ruxolitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 15/20 | 1.00 |
| ▸ | JAK1 known ✓ | P23458 | 14/20 | 1.00 |
| ▸ | JAK3 known ✓ | P52333 | 6/20 | 1.00 |
| ▸ | TYK2 known ✓ | P29597 | 3/20 | 1.00 |
| ▸ | ABL1 | P00519 | 3/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 2/20 | 1.00 |
| ▸ | PAK4 | O96013 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | LTK | P29376 | 2/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 1.00 |
| ▸ | CLK2 | P49760 | 2/20 | 1.00 |
| ▸ | TNK2 | Q07912 | 2/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 2/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 2/20 | 1.00 |
| ▸ | IKBKE | Q14164 | 2/20 | 1.00 |
| ▸ | NTRK3 | Q16288 | 2/20 | 1.00 |
| ▸ | NTRK2 | Q16620 | 2/20 | 1.00 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 1.00 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 1.00 |
| ▸ | CAMK1D | Q8IU85 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ruxolitinib SCHEMBL29349794 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3ABL1TYK2 | |
| Ruxolitinib SCHEMBL29677353 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3ABL1TYK2 | |
| Ruxolitinib SCHEMBL26927161 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3ABL1TYK2 | |
| Ruxolitinib SCHEMBL99225 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3ABL1TYK2 | |
| Ruxolitinib SCHEMBL31247553 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3ABL1TYK2 | |
| Ruxolitinib SCHEMBL171319 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3ABL1TYK2 | |
| Ruxolitinib SCHEMBL26927158 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3ABL1TYK2 | |
| Ruxolitinib SCHEMBL29808249 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3ABL1TYK2 | |
| SCHEMBL99371 | 0.99 | JAK2 (0.98) | JAK2JAK1JAK3ABL1TYK2 | |
| SCHEMBL99245 | 0.99 | JAK2 (0.98) | JAK2JAK1JAK3ABL1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 894 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4011883-B1 | SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H- PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | INCYTE HOLDINGS CORP (US) | 2025-04-23 | — | — | EP | claimed |
| EP-4501409-A2 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | Incyte Holdings Corporation (US) | 2025-02-05 | — | — | EP | claimed |
| EP-4491175-A1 | A SOLID ORAL COMPOSITION OF RUXOLITINIB | Genepharm S.A. (GR) | 2025-01-15 | — | — | EP | claimed |
| US-20240293411-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | INCYTE CORPORATION | 2024-09-05 | — | — | US | claimed |
| US-20240091234-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | INCYTE CORPORATION | 2024-03-21 | — | — | US | claimed |
| US-20240041887-A1 | COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR | INCYTE CORP (US) | 2024-02-08 | — | — | US | claimed |
| CN-117120055-A | Combination therapy comprising a JAK pathway inhibitor and a ROCK inhibitor | 因赛特公司 | 2023-11-24 | — | — | CN | claimed |
| EP-3838903-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2023-11-22 | — | — | EP | claimed |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | claimed |
| US-11738026-B2 | Combination therapy comprising an ALK2 inhibitor and a JAK2 inhibitor | INCYTE CORPORATION (US) | 2023-08-29 | — | — | US | claimed |
| WO-2010039939-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION (US) | 2010-04-08 | — | — | WO | claimed |
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporationn, a Delaware corporation | 2010-01-28 | — | — | US | claimed |
| US-7598257-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2009-10-06 | — | — | US | claimed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | claimed |
| CN-101448826-A | Heteroaryl substituted pyrrolo [2 ] as janus kinase inhibitors | INCYTE CORP (US) | 2009-06-03 | — | — | CN | claimed |
| WO-2008157208-A2 | SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | INCYTE CORPORATION (US) | 2008-12-24 | — | — | WO | claimed |
| US-20080312259-A1 | SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | INCYTE CORPORATION (US) | 2008-12-18 | — | — | US | claimed |
| EP-1966202-A1 | HETEROARYL SUBSTITUTED PYRROLOÝ2,3-B¨PYRIDINES AND PYRROLOÝ2,3-B¨PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporation (US) | 2008-09-10 | — | — | EP | claimed |
| WO-2007070514-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-B]PYRIDINES AND PYRROLO[2,3-B]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2007-06-21 | — | — | WO | claimed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11738026-B2 | Combination therapy comprising an ALK2 inhibitor and a JAK2 inhibitor | ALK, JAK2, ABL2 | JAK2 2/4885JAK1 5/4885JAK3 7/4885 |
| US-20080312259-A1 | SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885JAK3 2/4885 |
| US-20240041887-A1 | COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR | ALK, JAK2, ABL2 | JAK2 2/4885JAK1 5/4885JAK3 7/4885 |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | JAK1, JAK3, MAP3K4 | JAK2 4/4885JAK1 1/4885JAK3 2/4885 |
| US-20240091234-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | JAK2, JAK1, BTK | JAK2 1/4885JAK1 2/4885JAK3 4/4885 |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885JAK3 1/4885 |
| US-20240293411-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | JAK1, ROCK1, JAK3 | JAK2 8/4885JAK1 1/4885JAK3 3/4885 |
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885JAK3 1/4885 |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885JAK3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.